Getinge AB stock (SE0000202624): Medical device leader in surgical and critical care

Getinge AB, a global leader in medical devices for operating rooms and intensive care, continues to drive innovation amid growing demand in healthcare infrastructure worldwide.

Getinge AB recently highlighted its position in the expanding surgical booms market, alongside competitors like Stryker Corporation, as noted in a market report published on openPR. The company, known for equipment in patient monitoring and sterilization, maintains a strong presence in healthcare technology. Getinge AB stock (SE0000202624) trades on the Nasdaq Stockholm exchange, offering exposure to the medtech sector for US investors tracking international healthcare plays.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Getinge AB
• Sector/industry: Medical devices and healthcare equipment
• Headquarters/country: Sweden
• Core markets: Europe, North America, Asia
• Key revenue drivers: Surgical equipment, patient monitoring, sterilization systems
• Home exchange/listing venue: Nasdaq Stockholm (GETI B)
• Trading currency: SEK

Getinge AB: core business model

Getinge AB develops and sells medical devices and systems for operating rooms, intensive care units, and sterilization processes. The company serves hospitals and clinics globally with products like surgical tables, anesthesia machines, and patient monitoring solutions. Its business model focuses on lifecycle management, providing maintenance and upgrades to ensure long-term equipment reliability, according to the company's investor relations page as of 2026 at Getinge IR as of 2026.

Revenue is generated through direct sales, service contracts, and consumables. Getinge emphasizes innovation in areas like infection control and digital health integration, positioning it well in mature healthcare markets. For US investors, Getinge's exposure to North American hospitals provides a link to domestic healthcare spending trends.

Main revenue and product drivers for Getinge AB

Getinge's primary revenue comes from its Acute Care and Life Science segments. Acute Care, which includes surgical and ICU equipment, accounts for the majority of sales. Key products feature in market analyses, such as surgical booms, where Getinge is listed as a major player per a report on openPR as of recent.

Life Science drives growth through sterilization and lab equipment. The company benefits from rising global demand for hospital infrastructure upgrades post-pandemic. US relevance stems from partnerships and sales in American healthcare facilities.

Industry trends and competitive position

The medtech sector sees steady growth from aging populations and elective surgery recovery. Getinge competes with Stryker, Medtronic, and Philips in niches like OR integration. Its focus on sustainability and digital solutions aligns with industry shifts toward efficient healthcare delivery.

Why Getinge AB matters for US investors

US investors gain exposure to European medtech via Getinge, listed as an ADR in some markets. The company's North American revenue, around 25-30% historically, ties it to US hospital expansions and Medicare trends. Nasdaq Stockholm listing facilitates trading for international portfolios.

Conclusion

Getinge AB remains a key player in medical equipment, with strengths in surgical and critical care solutions. Recent market mentions underscore its competitive standing. Investors monitor global healthcare demand and innovation pipelines for ongoing developments. The stock reflects broader medtech dynamics relevant to diversified portfolios.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.